Cancer Radiother. 2021 Oct 25:S1278-3218(21)00252-3. doi: 10.1016/j.canrad.2021.08.018. Online ahead of print.
ABSTRACT
Chemoradiotherapy with concurrent cisplatin has been the standard treatment for locally advanced head and neck squamous cell carcinoma (HNSCC) for over 20 years. Recently, immunotherapy, a new therapeutic class, has emerged for patients with recurrent or metastatic HNSCC and has significantly extended their survival. Will it bring the same benefit to patients with localized tumors? There is a strong rationale for combining radiation therapy and checkpoint inhibitors for HNSCC. Indeed, radiation therapy can have both immunostimulatory and immunomodulatory effects. This is what explains the famous abscopal effect. The aim of this review is to present the data available on the combination of radiation therapy and immunotherapy for HNSCC.
PMID:34711485 | DOI:10.1016/j.canrad.2021.08.018
No comments:
Post a Comment